PMID- 29872875
OWN - NLM
STAT- MEDLINE
DCOM- 20190801
LR  - 20190801
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Print)
IS  - 0344-5704 (Linking)
VI  - 82
IP  - 2
DP  - 2018 Aug
TI  - Efficacy of capecitabine in patients with locally advanced or metastatic breast 
      cancer with or without prior treatment with fluoropyrimidine: a retrospective 
      study.
PG  - 275-283
LID - 10.1007/s00280-018-3617-5 [doi]
AB  - PURPOSE: We conducted a retrospective study to assess the outcomes of 
      capecitabine for advanced breast cancer (ABC) after perioperative 
      fluoropyrimidines (FPs). METHODS: The charts of patients with ABC who received 
      capecitabine between 2008 and 2016 at the National Cancer Center Hospital (Tokyo, 
      Japan) were reviewed. Progression-free survival (PFS), overall survival (OS), 
      tumor response, and adverse events (AEs) were compared between two groups: an FP 
      group (prior perioperative FP use) and a non-FP group (no prior FP use). RESULTS: 
      Overall, 288 patients (FP n = 105; non-FP n = 183) were analyzed. The two groups 
      had similar patient characteristics. The FP group had significantly poorer PFS 
      than the non-FP group (multivariate hazard ratio [HR] 1.33; 95% confidence 
      interval [CI] 1.02-1.73; p = 0.036), although the OS did not differ significantly 
      between the groups (multivariate HR 1.00; 95% CI 0.67-1.50; p = 0.994). With 
      different cut-off values (relapse-free interval [RFI] = 3, 4, and 5 years), 
      multivariate HRs for PFS were 1.32-1.67 (short RFI), and 1.00-1.25 (long RFI). A 
      trend for a larger HR in the FP group compared to the non-FP group with short RFI 
      than in that with long RFI was also seen for OS. Response rate (RR) and disease 
      control rate (DCR) did not differ significantly between the groups (RR in FP vs 
      non-FP 13.8 vs 21.0%; p = 0.173; DCR 54.0 vs 59.9%; p = 0.418). No significant 
      difference in AEs existed between the groups. CONCLUSIONS: Extra caution is 
      needed when capecitabine is considered for patients with ABC who used 
      perioperative FP, especially those who had early recurrence.
FAU - Iizumi, Sakura
AU  - Iizumi S
AUID- ORCID: 0000-0001-6760-152X
AD  - Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
AD  - Keio University Graduate School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 
      160-8582, Japan.
FAU - Shimomura, Akihiko
AU  - Shimomura A
AUID- ORCID: 0000-0002-2557-8170
AD  - Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. ashimomu@ncc.go.jp.
FAU - Shimoi, Tatsunori
AU  - Shimoi T
AD  - Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Sudo, Kazuki
AU  - Sudo K
AD  - Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Noguchi, Emi
AU  - Noguchi E
AD  - Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Yonemori, Kan
AU  - Yonemori K
AD  - Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Shimizu, Chikako
AU  - Shimizu C
AD  - Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Fujiwara, Yasuhiro
AU  - Fujiwara Y
AD  - Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Tamura, Kenji
AU  - Tamura K
AD  - Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180605
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Pyrimidines)
RN  - 6804DJ8Z9U (Capecitabine)
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antimetabolites, Antineoplastic/therapeutic use
MH  - Breast Neoplasms/*drug therapy
MH  - Capecitabine/*therapeutic use
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Pyrimidines/therapeutic use
MH  - Retrospective Studies
PMC - PMC6060805
OTO - NOTNLM
OT  - Breast neoplasms
OT  - Capecitabine
OT  - Efficacy
OT  - Fluoropyrimidine
OT  - Safety
COIS- CONFLICT OF INTEREST: The authors have declared no conflicts of interest. ETHICAL 
      APPROVAL: This article does not contain any interventional studies with human 
      participants performed by any of the authors. This study was approved by the 
      ethics committee of each participating hospital and was performed in accordance 
      with the 1964 Helsinki declaration and its later amendments or comparable ethical 
      standards. INFORMED CONSENT: Informed consent was not required for this study.
EDAT- 2018/06/07 06:00
MHDA- 2019/08/02 06:00
PMCR- 2018/06/05
CRDT- 2018/06/07 06:00
PHST- 2017/11/15 00:00 [received]
PHST- 2018/05/31 00:00 [accepted]
PHST- 2018/06/07 06:00 [pubmed]
PHST- 2019/08/02 06:00 [medline]
PHST- 2018/06/07 06:00 [entrez]
PHST- 2018/06/05 00:00 [pmc-release]
AID - 10.1007/s00280-018-3617-5 [pii]
AID - 3617 [pii]
AID - 10.1007/s00280-018-3617-5 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2018 Aug;82(2):275-283. doi: 
      10.1007/s00280-018-3617-5. Epub 2018 Jun 5.